CARB survey
This article was originally published in The Rose Sheet
Executive Summary
The California Air Resources Board's proposed 2003 Consumer & Commercial Products Survey has been amended to include 300 categories, down from 500, agency reports during Sept. 30 workshop. CARB notes remaining 200 categories will be included in the 2005 survey. Among new categories in the 2003 survey is witch hazel. The Cosmetic Toiletry and Fragrance Association has argued personal care categories with little or no volatile organic compound emissions should be excluded from the survey, expected to be released this month (1"The Rose Sheet" Sept. 20, 2004, p. 3). Agency also announces it will evaluate hair spray ingredient aminomethyl propanol to determine whether it should be considered a VOC. Until now, AMP has been considered a low vapor pressure, but data indicate the compound may have a vapor pressure in the VOC range, according to CARB. Board will hold three workshops in October to "discuss potential updates to the state's emission inventory" including an Oct. 19 workshop in Sacramento, an Oct. 20 meeting in Del Monte and an Oct. 22 meeting in Fresno...
You may also be interested in...
CARB Survey Proposal Will Result In Category Confusion – J&J
Inferences drawn from the California Air Resources Board's proposed 2003 Consumer & Commercial Products Survey will be biased based upon the categories companies choose to classify their products, Johnson & Johnson Consumer Products division says in comments to the agency Sept. 7
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.